Diabetes drug ACTOS® (pioglitazone HCl) showed anti-inflammatory effects


San Diego, CA, June 11, 2005 - A new study presented today at the American Diabetes Association (ADA) 65th Annual Scientific Sessions showed that the type 2 diabetes drug ACTOS reduced C-reactive protein (CRP), a marker of inflammation and a risk factor for cardiovascular disease.

"This study contributes to increasing data pool suggesting that ACTOS may have benefits beyond blood glucose control and an improvement in insulin resistance, although further studies are required," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America.

Study Design

The study found that treatment with ACTOS reduced levels of CRP and interleukin (IL-6), both of which are markers of inflammation in patients with type 2 diabetes. In this randomized, placebo-controlled, double-blind study, patients with stable glycemic control receiving insulin with or without metformin were randomized to add-on therapy with ACTOS (15 mg/day titrated to 30 mg/day, if tolerated) or placebo.

After eight to ten weeks, there were significantly greater decreases in levels of the two markers in the ACTOS arm. CRP decreased by 6.98 mg/L compared to 1.55 mg/L for placebo (p= 0.001). IL-6 decreased by 0.78 pg/mL compared to 0.22 pg/ml for placebo (P=0.002).

Cardiovascular Disease and Diabetes

In recent years, scientists and physicians are recognizing a growing association of two epidemic diseases " cardiovascular disease and diabetes. "CardioDiabetes" is a term being used to refer to this association. According to a joint American Heart Association and American Diabetes Association consensus statement, diabetes is an independent risk factor for cardiovascular disease. In fact, some experts are of the opinion that "diabetes is a cardiovascular disease."

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.